Sanofi Joins mRNA COVID-19 Club With Translate Tie-Up
Two-Pronged Approach For A Coronavirus Vaccine
Executive Summary
The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.
You may also be interested in...
Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy
Fast and furious and slow and steady may both be winning strategies in the race to protect the populace from COVID-19, said Sanofi’s Paul Hudson and John Reed, as the firm accelerated the timeline for its recombinant protein-based vaccine in development with GSK.
Sanofi Vaccines Chief Loew To Be Ipsen CEO
Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.
Sanofi Calms France's Fears Over COVID-19 Vaccine Access
Paul Hudson has been at the helm of Sanofi for just nine months, but for the last few days his comments about which country will be first in line for the firm's coronavirus vaccines will have reminded him that the Gallic culture runs deep.